It has been previously shown that, compared to patients with solid tumors and healthy individuals, in patients with hematologic malignancies, T cell immune responses are reduced both after COVID-19 infection and post-vaccination, with CD4+ T cells playing a principal role in comparison to CD8+ (24, 32, 35–37, 40). Here, CD4 is linked to hematologic disorder.